aTyr Pharma Q3 2024 Earnings Report

aTyr Pharma EPS Results

• Actual EPS: -$0.23
• Consensus EPS: -$0.22
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

aTyr Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.13 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

aTyr Pharma Announcement Details

• Quarter: Q3 2024
• Date: 11/7/2024
• Time: After Market Closes
• Conference Call Date: Thursday, November 7, 2024
• Conference Call Time: 4:00PM ET

aTyr Pharma (NASDAQ:ATYR) (NASDAQ:ATYR) is a clinical-stage biotechnology company focused on the discovery and development of novel protein therapeutics that harness the body’s natural processes to treat severe diseases. Founded as a spin-out from leading academic research institutions, the company pioneers the field of extracellular modulation of intracellular targets through its proprietary XCEPTOR platform. This technology leverages engineered proteins derived from aminoacyl tRNA synthetases to regulate cellular stress responses, offering a new modality for treating inflammatory, fibrotic and immune-mediated disorders.

The company’s lead clinical candidate, ATYR1923 (resolaris), is an engineered human protein designed to bind to neuropilin-2 and modulate immune activity in the lung. ATYR1923 is being evaluated in patients with pulmonary sarcoidosis and other interstitial lung diseases, where inflammation and fibrosis can cause progressive respiratory impairment. Earlier-stage programs target indications such as pulmonary arterial hypertension and select oncology settings, illustrating aTyr’s commitment to translating its platform across therapeutic areas with high unmet medical need.

Headquartered in San Diego, California, aTyr Pharma conducts research and development operations in the United States and collaborates with academic centers and industry partners in North America and Europe. The company maintains active clinical trial sites across multiple geographies to support robust patient enrollment and regulatory engagement. Its approach combines late-stage development rigor with the agility of a focused biotech, aiming to advance candidates efficiently through clinical milestones.

aTyr is led by a seasoned management team with extensive experience in biopharmaceutical R&D, regulatory affairs and commercial strategy. The board and executive officers bring expertise from established life science companies, with a shared vision of delivering differentiated protein therapeutics. With its innovative platform and advancing clinical pipeline, aTyr Pharma seeks to offer new treatment options for patients suffering from debilitating diseases driven by inflammatory and fibrotic pathways.